News & Events
September 12, 2023
C-Path’s Rare Disease Clinical Outcome Assessment Consortium Launches Rare Disease COA ResourceThe Rare Disease COA Resource aims to simplify COA selection for use in rare disease drug development. TUCSON, Ariz., September 12, 2023 — The Rare Disease Clinical Outcome Assessment (COA) Consortium at Critical Path Institute (C-Path), a public-private partnership focused on optimizing COA selection during drug development for rare diseases, today announced the launch......
July 18, 2023
C-Path Integrates European Offices to Optimize Global Operations and Collaborative Partnerships
C-Path ts activity in Europe and broaden its global operations. C-Path operates in Europe as a nonprofit organisation that builds consensus among its stakeholders from around the world to improve public health. The organisation shares expertise, data, risks and costs to move regulatory science forward.
April 25, 2023
C-Path Europe: A Global Vision of SuccessTUCSON, Ariz. and AMSTERDAM, April 26, 2023 — As an organization that generates regulatory-endorsed solutions and methodologies to accelerate drug development, Critical Path Institute (C-Path) today shared a year-in-review of its European-focused activities to advance global regulatory science. “We are pleased with the progress and continued development of our global efforts in the regulatory and......
March 29, 2023
C-Path Appoints Key Scientific Leaders to Executive RolesTUCSON, Ariz., March 29, 2023 — Critical Path Institute (C-Path) announced today the appointment of three accomplished leaders to key executive roles within the organization. Cheryl D. Coon, Ph.D., joins C-Path as the Vice President for the Clinical Outcome Assessment (COA) Program. Shu Chin Ma, Ph.D., M.Sc., M.Phil., EMBA, has been named Vice President of......
September 27, 2022
Global Biopharmaceutical Leader to Usher C-Path in Next Phase of Growth and Innovation
C-Path today named Daniel M. Jorgensen, M.D., MPH, MBA, its Chief Executive Officer (CEO). An experienced leader in drug development, healthcare and business, Jorgensen will continue C-Path’s distinguished reputation of collaboration with global stakeholders, including patient groups, academic institutions, the pharmaceutical industry and regulatory agencies, to set a vision for C-Path’s next phase of growth and innovation. Jorgensen’s tenure as CEO will commence on the first of October.